Skip to main content

Medical materials

Publication
  • EAHAD
  • 7 February, 2025

Efanesoctocog Alfa for the Perioperative Management of Patients with Severe Haemophilia A: 4 years of Experience in the XTEND Clinical Program

Anthony K. C. Chan, Flora Peyvandi, Annette von Drygalski, Sandrine Meunier, Elena Santagostino, Linda Bystrická, Jennifer Dumont , Lara Mamikonian, Umer Khan, Liane Khoo, Robert Klamroth

Available materials

Publication
  • EAHAD
  • 7 February, 2025

Two-Year Clinical Outcomes of Once-Weekly Efanesoctocog Alfa Prophylaxis in Children with Severe Hemophilia A: Second Interim Analysis of the XTEND-ed Phase 3 Study

Lynn Malec, Beatrice Nolan, Anthony K. C. Chan, Manuela Albisetti, Sheng-Chieh Chou, Bulent Zulfikar, Mindy Simpson, Liqi Feng, Helena Palmborg, Graham Neill, Lydia Abad-Franch, Sriya Gunawardena, Karin Fijnvandraat

Available materials

Publication
  • EAHAD
  • 5 February, 2025

Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Adults from the 48-Month Prospective, Observational A-MORE Study

Olga Benitez Hidalgo, Anna Olsson, Karina Meijer, Carmen Escuriola-Ettingshausen, Flora Peyvandi, Andreu Schoenenberger López, Markus Fusser, Stefan Lethagen

Available materials

Publication
  • EAHAD
  • 5 February, 2025

Real-World Effectiveness and Usage of a Recombinant Factor VIII Fc: Interim Analysis in Children and Adolescents from the 48-Month Prospective, Observational A-MORE Study

Martin Olivieri, Pasi Huttunen, Chiara Biasoli, Christoph Königs, Barbara Faganel Kotnik, Andreu Schoenenberger López, Markus Fusser, Stefan Lethagen

Available materials

Publication
  • EAHAD
  • 5 February, 2025

Clinical outcomes over 3 years of efanesoctocog alfa in adults and adolescents with severe haemophilia A: European results from the second interim analysis of XTEND-ed

Robert Klamroth, Pratima Chowdary, Toshko Lissitchkov, María Teresa Álvarez Román, Umer Khan, Linda Bystrická, Elena Santagostino, Sophie Susen

Available materials

Publication
  • EAHAD
  • 5 February, 2025

Clinical outcomes over 2 years of efanesoctocog alfa in children with severe haemophilia A: European results from the second interim analysis of XTEND-ed

Karin Fijnvandraat, Manuela Albisetti, Bulent Zulfikar, Umer Khan, Helena Palmborg, Lydia Abad-Franch, Beatrice Nolan

Available materials

Publication
  • EAHAD
  • 5 February, 2025

Patient characteristics in FREEDOM, a study evaluating physical activity and joint health in patients with haemophilia A receiving efanesoctocog alfa prophylaxis

Jan Astermark, Ruben Berrueco, Giancarlo Castaman, Susan Shapiro, Helena Ahlin, Jenny Björkqvist, Markus Fusser, Pål A. Holme

Available materials

Publication
  • EAHAD
  • 5 February, 2025

Assessment of treatment schedule, factor VIII trough level, and area under the curve for efanesoctocog alfa vs an extended half-life FVIII comparator: a modelling approach

Sarah Brighton, Nana Kragh, Judith Thanner, Nicoletta Martone, Tom Burke, Enrico Ferri Grazzi

Available materials

Publication
  • EAHAD
  • 5 February, 2025

Impact of a hypothetical switch to efanesoctocog alfa prophylaxis on bleeding, treatment burden and area under the curve in severe haemophilia A: Italian CHESS III cohort analysis

Enrico Ferri Grazzi, Sarah Brighton, Nana Kragh, Judith Thanner, Nicoletta Martone, Tom Burke

Available materials

Symposium
  • EAHAD
  • 5 February, 2025

Entering a New Era in Protection in Haemophilia A

Jan Astermark, Maria Elisa Mancuso, Christoph Königs, Robert Klamroth

Available materials

Publication
  • EAHAD
  • 5 February, 2024

Treatment of Bleeding Episodes with Efanesoctocog Alfa in Adults and Adolescents with Severe Haemophilia A: Second Interim Analysis of the XTEND-ed Long-term Extension Study

Johannes Oldenburg, Sandrine Meunier, Nobuaki Suzuki, Linda Bystrická, Graham Neill, Lydia Abad-Franch, Lara Mamikonian, Angela Weyand

Available materials

Sign up for alerts